What insurance policy changes affect Family Medicine providers?

Family Medicine providers face policy updates from major payers including prior authorization requirements, billing code changes, reimbursement rate adjustments, and coverage criteria revisions. PolicyChanges.app tracks these updates daily across all major insurers.

How often do insurance policies change for Family Medicine?

Insurance payers publish policy changes on rolling schedules: some quarterly, some monthly, and some with immediate effect. Family Medicine practices typically see dozens of relevant changes per year across their contracted payers.

How do I get notified of new Family Medicine policy changes?

Sign up for a free PolicyChanges.app account and create a saved search filtered to Family Medicine. You will receive a daily digest whenever a new policy change matches your specialty filter.

Which payers post the most policy changes affecting Family Medicine?

Based on tracked changes, Family Medicine updates have come from payers including Healthfirst, Illinois Medicaid - HFS, Health Net, UnitedHealthcare, Sentara Health Plans.

Family Medicine Insurance Policy Changes

Keeping up with insurance policy changes that affect Family Medicine practices is a full-time job. This page aggregates the latest payer updates (prior authorization rule changes, reimbursement adjustments, billing code additions and removals, and coverage policy revisions) across all major insurers. Changes are identified and summarized daily so Family Medicine providers and their billing teams can act before deadlines pass.

Medium impact

Denosumab Products: (Prolia®); Denosumab-nxxp (Bildyos®); Denosumab-mobz (Boncresa);Denosumab-kyqq (Bosaya™); Denosumab-bnht (Conexxence®); Denosumab-qbde (Enoby™); Denosumab-bbdz (Jubbonti®); Denosumab-dssb (Ospomyv™); Denosumab-desu (Osvyrti); Denosumab-bmwo (Stoboclo®)

BCBS Tennessee·Effective Jul 31, 2026

New comprehensive policy for denosumab products (Prolia and 9 biosimilars) establishes specific coverage criteria, prior authorization requirements, and documentation standards for osteoporosis, cancer-related bone loss, and rheumatoid arthritis treatments. The policy includes detailed approval criteria for different patient populations and sets 12-month authorization periods with specific continuation requirements.

Healthfirst Lab Reimbursement Policy Updates

Coding Update for Behavioral Health Screenings Effective August 1, 2026

26-809 New Requirement: Submit Medi-Cal Provider Onboarding Training Attestation Online

Medicare in AL, AR & SC: New DME process for select members

Medical and Clinical Policy Updates - Effective August 1, 2026

[Ohio] Evaluation and Management (E/M) and Psychotherapy Add-On Billing Policy

Language Clarification: Proper Use of Modifier 25 When Billing for Allergy Testing and E/M Services on the Same Day

Medicare: New DME process for select members in multiple states

26-851 Definitive Drug Testing Billing Change, Effective October 1, 2026

COVID-19 Laboratory Tests Reimbursement Changes for Urgent Care Centers and Convenience Care Clinics

Important Changes to Board-Registered Associates Billing

HealthHelp to Manage Molecular Lab Prior Authorization

Drug Policy Criteria Change

NC Integrated Care for Kids Closeout and Related Billing Code Changes

Transition to American Medical Association Maternity Current Procedural Terminology 2027 Code Changes Effective Jan. 1, 2027

New Electronic Remit Regeneration Requests on the eMedNY Website

New York State Medicaid Prescriber Education Program: Free 1.5 Hour Continuing Education on Antibiotic Stewardship

New York State Medicaid Evidence Based Benefit Review Advisory Committee to Review AI-Enabled Devices for Diabetic Retinopathy Screening

Billing for Services Provided to the Office of Mental Health Residential Treatment Facility Residents

Reminder: Medicaid Attestation Required for New York State Medicaid Members Enrolled in Qualifying Clinical Trials

New York State Medicaid Coverage of Basivertebral Nerve Ablation

Increase in Reimbursement for Article 28 Clinic Providers Delivering Mental Health Services

Childhood Vaccine Counseling

New York State Medicaid Coverage of Breast Cancer Screening, Imaging, and Testing for Management and Treatment

New PA Timelines:

Prior Approval Changes Effective January 1, 2027

ForwardHealth Update 2026-08: For Prenatal Care Coordination Providers: Milwaukee County Transition and Statewide Changes to Memoranda of Understanding Requirement

Zoledronic Acid (Reclast®)

Romosozumab-aqqg (Evenity®)

Noninvasive Imaging Techniques for Evaluation and Monitoring of Chronic Liver Diseases

Inclisiran (Leqvio®)

Denosumab Products: (Prolia®); Denosumab-nxxp (Bildyos®); Denosumab-mobz (Boncresa);Denosumab-kyqq (Bosaya™); Denosumab-bnht (Conexxence®); Denosumab-qbde (Enoby™); Denosumab-bbdz (Jubbonti®); Denosumab-dssb (Ospomyv™); Denosumab-desu (Osvyrti); Denosumab-bmwo (Stoboclo®)

Immunization Fee Schedule (NIIFS) quarterly update

MAB2026072801

Do you have time for a Quality Minute about pharmacy measures?

Pharmacy coverage changes

August 2026 TMPPM Update for Clinician Administered Drug Vitamin B12 (Cyanocobalamin) Injection

Nutritional Therapy and Nutritional Counseling

BT202684: Pharmacy updates approved by Drug Utilization Review Board May 2026

Non-Invasive Prenatal Testing - (Effective Date - 2026-08-17) 2.02.25

Inclisiran (Leqvio®)

Reimbursement Policy Updates

Policy Criteria Change-Material Amendment

Referrals to home healthcare for Medicare Advantage members: Grace period extended through Sept. 30 for acute care providers

COVID-19 testing—Molecular and antigen updates eff. 10/1/2026

[California] Carelon Medical Benefits Management updates

Reminder of Patient-Centered Medical Home (PCMH) Recognition Attestation Deadline

[Ohio] Precertification/prior authorization requirement updates — Carelon Medical Benefits Management (July 2026 Newsletter)

Mutual News August 2026 Newsletter

Prioritizing early mental health and substance use screening in 2026-2027